Covered recipient · General Payments record
EDWARD B GARON
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$106,965.77
81 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $63,945.31 | 24 |
| Travel and Lodging | $41,555.75 | 29 |
| Food and Beverage | $1,464.71 | 28 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $54,873.72 | 29 |
| Regeneron Pharmaceuticals, Inc. | $14,853.36 | 11 |
| E.R. Squibb & Sons, L.L.C. | $11,701.00 | 2 |
| Samsung Bioepis Co., Ltd. | $6,305.35 | 5 |
| AstraZeneca Pharmaceuticals LP | $4,992.50 | 3 |
| GENZYME CORPORATION | $3,597.06 | 4 |
| Gilead Sciences, Inc. | $3,507.95 | 6 |
| GlaxoSmithKline, LLC. | $3,002.11 | 4 |
| ABBVIE INC. | $2,537.50 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $1,430.24 | 14 |
| Mirati Therapeutics, Inc. | $164.98 | 2 |
Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EDWARD B GARON
NPI 1134153745 · CMS profile ID 50938
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EDWARD B GARON, NPI 1134153745, CMS profile ID 50938. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). EDWARD B GARON, NPI 1134153745, CMS profile ID 50938. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- EDWARD B GARON, NPI 1134153745, CMS profile ID 50938, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
81 matching records · $106,965.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–81 of 81.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $23.14 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225546899 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $57.24 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225546903 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $170.42 | 05/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225546905 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $217.10 | 05/01/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225546913 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $35.16 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1225546917 | CMS |
| Gilead Sciences, Inc. | $2,910.00 | 04/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234351454 | CMS |
| Gilead Sciences, Inc. | $27.38 | 04/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234373749 | CMS |
| Gilead Sciences, Inc. | $18.69 | 04/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234374155 | CMS |
| Merck Sharp & Dohme LLC | $10,240.00 | 04/07/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237999110 | CMS |
| Merck Sharp & Dohme LLC | $150.00 | 04/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238032328 | CMS |
| Gilead Sciences, Inc. | $489.34 | 03/27/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234366001 | CMS |
| Gilead Sciences, Inc. | $48.52 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234414550 | CMS |
| Gilead Sciences, Inc. | $14.02 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234577327 | CMS |
| Merck Sharp & Dohme LLC | $27.24 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237998490 | CMS |
| Merck Sharp & Dohme LLC | $13,326.71 | 03/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238030036 | CMS |
| Merck Sharp & Dohme LLC | $47.14 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238030258 | CMS |
| Merck Sharp & Dohme LLC | $218.05 | 03/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238032874 | CMS |
| Merck Sharp & Dohme LLC | $36.67 | 03/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238035870 | CMS |
| Merck Sharp & Dohme LLC | $217.27 | 03/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1237996900 | CMS |
| Merck Sharp & Dohme LLC | $90.89 | 03/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238032400 | CMS |
| Regeneron Pharmaceuticals, Inc. | $416.97 | 03/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238025 | CMS |
| Regeneron Pharmaceuticals, Inc. | $73.17 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238027 | CMS |
| Regeneron Pharmaceuticals, Inc. | $94.45 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238029 | CMS |
| Regeneron Pharmaceuticals, Inc. | $33.03 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238031 | CMS |
| Regeneron Pharmaceuticals, Inc. | $83.69 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238033 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,280.00 | 03/05/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206667291 | CMS |
| Regeneron Pharmaceuticals, Inc. | $172.90 | 03/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238023 | CMS |
| Regeneron Pharmaceuticals, Inc. | $185.90 | 02/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213238021 | CMS |
| Merck Sharp & Dohme LLC | $610.00 | 02/17/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238007340 | CMS |
| Merck Sharp & Dohme LLC | $610.00 | 02/17/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238038750 | CMS |
| ABBVIE INC. | $2,537.50 | 01/13/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201904801 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $776,072.77 | 52 |
| PY2024 | Recipient | $1,758.48 | 3 |
| PY2024 | Principal investigator | $667,633.26 | 39 |
| PY2023 | Principal investigator | $1,225,149.02 | 47 |
| PY2022 | Recipient | $2,675.00 | 3 |
| PY2022 | Principal investigator | $1,439,706.20 | 29 |
| PY2021 | Recipient | $749.32 | 1 |
| PY2021 | Principal investigator | $1,292,238.74 | 26 |
| PY2020 | Recipient | $17,080.73 | 11 |
| PY2020 | Principal investigator | $1,092,941.80 | 73 |
| PY2019 | Recipient | $2,000.00 | 1 |
| PY2019 | Principal investigator | $1,069,131.49 | 81 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
52 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,735.93 | 12/31/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations | No dispute reported | 06/30/2026 | 1232922836 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,009.88 | 12/31/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects KEYNOTE-407 | No dispute reported | 06/30/2026 | 1232925781 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,223.14 | 12/31/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non-Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT | No dispute reported | 06/30/2026 | 1232926051 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $12,869.00 | 12/22/2025 | Non-covered Recipient Entity The Regents Of The University Of California | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small | No dispute reported | 06/30/2026 | 1225414886 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $17,690.00 | 11/25/2025 | Non-covered Recipient Entity The Regents Of The University Of California | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small | No dispute reported | 06/30/2026 | 1225415422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $907.20 | 10/16/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136743 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,110.60 | 10/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223352962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45,375.56 | 09/25/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223352960 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,979.00 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136639 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,643.20 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136641 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,849.40 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136643 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,419.20 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136647 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,342.60 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136653 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $907.20 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $907.20 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,060.54 | 09/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136663 |
| Principal investigator 1 | Eli Lilly and Company | $51,656.00 | 08/28/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS | No dispute reported | 06/30/2026 | 1187873281 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $50,326.00 | 07/21/2025 | Non-covered Recipient Entity REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185554626 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $12,410.00 | 07/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252498373 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $24,820.00 | 07/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252498375 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $22,338.00 | 07/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252498377 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $4,983.00 | 07/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252498379 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,892.00 | 07/01/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252498381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $315.00 | 06/19/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,525.00 | 06/19/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 06/19/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136603 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,292.00 | 06/19/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% | No dispute reported | 06/30/2026 | 1184136605 |
| Principal investigator 1 | Eli Lilly and Company | $11,172.40 | 06/05/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A PHASE 1 STUDY OF ORAL LOXO-260 IN PATIENTS WITH RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION REFRACTORY TO SELECTIVE RET INHIBITORS | No dispute reported | 06/30/2026 | 1187873279 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $6,914.00 | 06/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497071 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $38,937.00 | 06/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497073 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $408.00 | 06/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497075 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $61,048.00 | 06/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,520.00 | 05/28/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223352958 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $55,646.00 | 05/27/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1236000300 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $25,854.30 | 05/22/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223352956 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $534.00 | 05/22/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497063 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $7,182.00 | 05/22/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497067 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,260.00 | 05/22/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497069 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,185.00 | 05/21/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects KEYNOTE-189 | No dispute reported | 06/30/2026 | 1232925847 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $180.00 | 05/15/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497065 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $41,400.00 | 05/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 1 Open-Label, Dose-escalated Trial of Tumor Necrosis Factor Alpha and Interleukin-2 coding Oncolytic Adenovirus TILT-123 in Combination with Pembrolizumab in Patients with Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1232932171 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,852.10 | 04/17/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497061 |
| Principal investigator 1 | Genentech, Inc. | $13,000.00 | 03/20/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | No dispute reported | 06/30/2026 | 1211554600 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $360.00 | 03/20/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497051 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $6,829.00 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497053 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,895.00 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497055 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $8,983.00 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497057 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $17,490.00 | 03/11/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | 81990 | No dispute reported | 06/30/2026 | 1252497059 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $23,771.70 | 02/20/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223352952 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $124,643.86 | 02/14/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 | No dispute reported | 06/30/2026 | 1236529976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15,708.00 | 02/06/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | U31402-A-U103 | No dispute reported | 06/30/2026 | 1223352954 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,598.76 | 01/27/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1236000298 |